<DOC>
	<DOCNO>NCT02227849</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy Canagliflozin ( TA-7284 ) combination GLP-1 analogue patient type 2 Diabetes 52 week .</brief_summary>
	<brief_title>Long-Term Safety Study Canagliflozin ( TA-7284 ) Combination With GLP-1 Analogue Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This open-label study evaluate long-term safety efficacy Canagliflozin ( TA-7284 ) Japanese patient type 2 diabetes mellitus , receive treatment GLP-1 analogue diet exercise inadequate glycemic control . The patient receive TA-7284 100mg orally 52 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<criteria>Patients receive stable dose regimen GLP1 analogue 12 week administration investigational dug Patients dietary management take therapeutic exercise diabetes 12 week administration investigational drug Patients HbA1c ≥7.0 % &lt; 10.5 % Patients administer diabetes therapeutic drug prohibit concomitant use within 12 week administration investigational drug Patients type 1 diabetes mellitus , diabetes mellitus result pancreatic disorder , secondary diabetes mellitus ( Cushing 's syndrome , acromegaly , etc . ) Patients severe diabetic complication ( proliferative diabetic retinopathy , stage 4 nephropathy , serious diabetic neuropathy ) Patients hereditary glucosegalactose malabsorption primary renal glucosuria Patients systolic blood pressure ≥160 mmHg diastolic blood pressure ≥100 mmHg Patients serious renal hepatic disease Patients eGFR &lt; 45 mL/min/1.73 m2 Patients excessive alcohol addict Patients require insulin therapy Patients pregnant , lactate probably pregnant patient patient agree contraception</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>insulin resistance</keyword>
</DOC>